PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC 2011 May 19.
Published in final edited form as:
PMCID: PMC3097422
NIHMSID: NIHMS292509

Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism

Abstract

Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown. We show that loss of AT2 expression accelerates the aberrant growth and rupture of the aorta in a mouse model of Marfan syndrome (MFS). The selective AT1 receptor blocker (ARB) losartan abrogated aneurysm progression in the mice; full protection required intact AT2 signaling. The angiotensin-converting enzyme inhibitor (ACEi) enalapril, which limits signaling through both receptors, was less effective. Both drugs attenuated canonical transforming growth factor–β (TGFβ) signaling in the aorta, but losartan uniquely inhibited TGFβ-mediated activation of extracellular signal–regulated kinase (ERK), by allowing continued signaling through AT2. These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in MFS and related disorders.

Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that includes a predisposition for aortic root aneurysm and aortic rupture. MFS is caused by a deficiency of the microfibrillar constituent protein fibrillin-1 that is imposed by heterozygous mutations in FBN1. In prior work, we demonstrated that transforming growth factor–β (TGFβ) signaling was elevated in affected tissues of mice heterozygous for a cysteine substitution in an epidermal growth factor–like domain of fibrillin-1 (Fbn1C1039G/+), the most common class of mutation in people with MFS (1-4). Many disease manifestations—including aortic aneurysm (1), developmental emphysema (2), myxomatous degeneration of the atrioventricular valves (3), and skeletal muscle myopathy (4)—are attenuated by systemic administration of a pan-specific polyclonal TGFβ-neutralizing antibody (TGFβNAb) in fibrillin-1–deficient mice. Similar protection was achieved by treating Fbn1C1039G/+ mice with the angiotensin II (AngII) type 1 (AT1) receptor blocker (ARB) losartan (1, 4). ARBs can attenuate TGFβ signaling in some tissues by lowering the expression of TGFβ ligands, receptors, and activators (5-7). In this mouse model of MFS, losartan's protection correlated with decreased phosphorylation and nuclear translocation of Smad2 (pSmad2), a direct effector of canonical TGFβ signaling, and decreased expression of prototypical Smad-dependent TGFβ-responsive gene products, such as connective tissue growth factor and collagens.

The contribution of AT2 to aortic aneurysm progression remains controversial. AT2 signaling can oppose AT1-mediated enhancement of TGFβ signaling in some cell types and tissues (Fig. 1A) (8, 9). It can also induce vascular smooth muscle cell (VSMC) apoptosis, theoretically contributing to aortic wall damage. Apoptosis was observed in cultured cells derived from end-stage aneurysms in people with MFS (10), but has not been found in early- or intermediate-stage aortic wall lesions in MFS mice (1). Vascular expression of AT2 is largely limited to prenatal life, but it may continue to be relevant postnatally in the context of certain disease states, as evidenced by the acceleration of inflammatory aneurysms in AngII-infused mice treated with an AT2 antagonist (11). In contrast, β-aminopropionitrile monofumarate (BAPN)–induced aortic aneurysm and dissection in rats, which was associated with increased expression of AT2 and VSMC apoptosis, was ameliorated by limiting AngII production with angiotensin-converting enzyme inhibitor (ACEi) but not by selective AT1 receptor blockade (12). AT2 signaling has the capacity to attenuate both canonical (Smad-dependent) and noncanonical (mitogen-activated protein kinase or MAPK) TGFβ signaling cascades, most notably the extracellular signal-regulated kinase (ERK), in some tissues (13, 14). Thus, AT2 signaling can both augment and inhibit the pathogenesis of aneurysm in pre-clinical models, and the mechanistic explanation for the discordance is unclear. This has direct clinical relevance, as it leaves open to question the relative therapeutic merits of selective AT1 blockade with ARBs versus limiting signaling through both AT1 and AT2 with ACEi, despite small trials suggesting that either approach has potential in MFS (15-17).

Fig. 1
The role of AngII in the aorta. (A) AngII acts on the AT1 receptor causing increased cellular proliferation, fibrosis, and matrix metalloproteinase–2and/or −9 (MMP2/9) activity while decreasing apoptosis. Conversely, the AT2 receptor is ...

To assess the role of the AT2 receptor in MFS, we bred mice with a disrupted Agtr2 allele (encoding AT2; AT2KO) (18, 19) with Fbn1C1039G/+ mice, our established model of MFS (20). Agtr2 is encoded on the X chromosome in humans and mice, and the AT2KO allele associates with loss of mRNA and protein expression, as assessed by radioligand binding, in either homozygous females or hemizygous males. The AT2KO mice develop normally, with no evidence of cardiovascular pathology or early mortality (21).

We followed the progression of aortic root aneurysm by echocardiogram until the mice were killed at 12 months (Fig. 1B). There was a small difference in aortic root size between wild-type (WT) and AT2KO mice (P < 0.05) at 2 months, but this difference was absent at all future time points (P = 0.70). The aortic root diameter of AT2KO:Fbn1C1039G/+ mice was significantly larger than that seen in Fbn1C1039G/+ mice at 2 months of age (P < 0.001), and this difference was maintained through to 12 months of life (P <0.05). The postnatal aortic root growth over 10 months was not different between Fbn1C1039G/+ mice with or without AT2 expression (P = 0.80). This could reflect postnatal waning of AT2 receptor expression, attainment of an absolute threshold of aortic root growth rate in AT2KO:Fbn1C1039G/+ mice, and/or the accelerated death observed in AT2KO: Fbn1C1039G/+ mice that effectively removed the most severely affected animals from later analyses. We found that 32% of AT2KO:Fbn1C1039G/+ mice died before the scheduled killing, compared with 12% of Fbn1C1039G/+ mice (P < 0.01) and 0% of AT2KO or WT mice (Fig. 1C). Growth of the more distal ascending aorta over 10 months was significantly greater in AT2KO:Fbn1C1039G/+ mice compared with Fbn1C1039G/+ littermates (P < 0.05), whereas there was no significant difference between WT, AT2KO, and Fbn1C1039G/+ mice (Fig. 1D).

Histological and morphometric analyses of the aortic media were performed at 12 months. AT2KO:Fbn1C1039G/+ mice showed medial thickening, reduced elastin content, and increased elastic fiber fragmentation (Fig. 2A and figs. S1 to S3) compared with Fbn1C1039G/+ or AT2KO mice (P < 0.01 for all comparisons). These parameters were not significantly different in AT2KO and WT mice (P = 0.07, P = 0.68, and P = 1.0, respectively). Therefore, the histological changes in the aorta paralleled the echocardiography findings, which supported the conclusion that AT2 receptor elimination exacerbates aortic disease in MFS mice.

Fig. 2
Therapeutic effects in the aorta. (A) WT (n = 5), AT2KO (n = 4), Fbn1C1039G/+ (n = 7), and AT2KO:Fbn1C1039G/+ (n = 7) mice. Verhoeff–Van Gieson (VVG) stain reveals diffuse fragmentation of elastic fibers and thickening of the media in Fbn1C1039G/+ ...

The potential for exacerbation of the MFS phenotype outside of the cardiovascular system was also assessed. At 12 months, excised lungs were inflated with agar, sectioned, and stained for histological and morphometric analyses (figs. S4 and S5). Increased distal airspace caliber, a marker of impaired distal alveolar septation and emphasematous lung disease, can be quantified by calculating a mean linear intercept (MLI). There was no significant difference in MLI between WT and AT2KO mice (P = 1.0). Compared with WT and AT2KO littermates, Fbn1C1039G/+ mice had a significant increase in MLI (P < 0.05), whereas AT2KO:Fbn1C1039G/+ mice had a yet further increase in MLI (P < 0.05). This confirms that AT2 receptor elimination can exacerbate the MFS phenotype outside of the cardiovascular system.

We next performed a head-to-head comparison of ACEi versus ARBs. Fbn1C1039G/+ mice and WT littermates were treated with hemodynamically equivalent doses (fig. S6) of either the ACEi enalapril (10 to 15 mg/kg of body weight per day) or the ARB losartan (40 to 60 mg/kg per day) (22), beginning at 8 weeks of age, and were assessed with serial echocardiograms. Aortic root growth over the 7 months of treatment was significantly greater in placebo-treated Fbn1C1039G/+ mice compared with WT littermates (P < 0.01), whereas losartan led to a significant regression in growth in Fbn1C1039G/+ mice (P < 0.0001), to rates that were significantly less than that seen in WT littermates (P < 0.0001) (1). It is noteworthy that losartan reduced aortic root growth in Fbn1C1039G/+ mice, but had no effect in WT littermates (P = 0.27). Enalapril treatment had significantly less effect than losartan in Fbn1C1039G/+ mice (P < 0.0001); in fact, it was only marginally better than placebo treatment (P = 0.05) (Fig. 2B). Enalapril was also no more beneficial than placebo in improving aortic architecture score in Fbn1C1039G/+ mice (P = 0.19), whereas losartan was significantly more beneficial than both placebo and enalapril treatment (P < 0.05 for both) (fig. S7).

We next assessed whether AT2 signaling is needed to achieve losartan's full therapeutic benefit. AT2KO:Fbn1C1039G/+ mice were treated with losartan from 8 weeks of age and followed by serial echocardiography until they were killed at 9 months of age (Fig. 2C). Although there was a trend for increased aortic root growth in AT2KO:Fbn1C1039G/+ mice compared with Fbn1C1039G/+ littermates (P = 0.06), the decrease in aortic root growth seen in AT2KO:Fbn1C1039G/+ mice treated with losartan was only 40% of that seen in Fbn1C1039G/+ animals that expressed AT2 (P < 0.001), despite there being no difference in blood pressure between the groups (Fig. 2C and fig. S6). The modest reduction in aortic root growth seen in losartan-treated AT2KO:Fbn1C1039G/+ mice was comparable to that previously observed with propranolol, and it may be similarly attributable to a decline in blood pressure rather than a modulation of cytokine signaling (1).

Together, these experiments suggest that AT2 signaling protectively modifies MFS and that the therapeutic effect of ACEi likely relates to AT1 receptor blockade or antihypertensive effects. In addition, we have shown that selective AT1 antagonism with the ARB losartan is beneficial in Fbn1C1039G/+ mice and that AT2 signaling is needed to achieve the full potential of ARBs. Both the canonical (Smad-dependent) and non-canonical (MAPK, predominantly ERK1/2 but also JNK in some experimental contexts) TGFβ signaling cascades are activated in Fbn1C1039G/+ mice in a TGFβ- and AT1 receptor–dependent manner (23). To investigate the mechanism of protection by AT2 receptor signaling, we monitored the status of both canonical and noncanonical TGFβ signaling in Fbn1C1039G/+ mice lacking the AT2 receptor or in response to losartan or enalapril treatment. Western blot analysis showed that Smad2 activation was significantly greater in the aortic root and proximal ascending aorta of Fbn1C1039G/+ mice compared with WT controls (P < 0.01) but that there was no significant difference between AT2KO:Fbn1C1039G/+ and Fbn1C1039G/+ mice (P = 0.30). In contrast, ERK1/2 activation was significantly greater in Fbn1C1039G/+ mice compared with WT littermates (P < 0.01) and was further increased in AT2KO:Fbn1C1039G/+ mice compared with Fbn1C1039G/+ (P < 0.01), AT2KO (P < 0.01), and WT littermates (P < 0.001) (Fig. 3A). The difference in ERK1/2 activation was specific to the aortic root and proximal ascending aorta, the areas most predisposed to aneurysm formation in MFS, as there was no significant difference in the descending thoracic aortas of the same animals (fig. S8). No significant differences in JNK1 or p38 activation were observed (fig. S9).

Fig. 3
Mechanism of protection by AT2 signaling. (A) Western blot analysis of ERK1/2 and Smad2 activation in the aortic root and proximal ascending aorta of four mice of each genotype. Note that Smad2 activation is increased equally in AT2KO:Fbn1C1039G/+ and ...

In our comparison of ARBs versus ACEi, Smad2 activation was significantly greater in Fbn1C1039G/+ mice compared with WT controls (P < 0.05), and losartan treatment significantly decreased Smad2 activation in Fbn1C1039G/+ mice (P < 0.05) to levels indistinguishable from WT (P = 0.31) (Fig. 3B). Enalapril reduced Smad2 activation in Fbn1C1039G/+ mice significantly more than losartan (P < 0.01), a finding that did not parallel the therapeutic effects of these agents (Fig. 2B). ERK1/2 activation was significantly greater in Fbn1C1039G/+ mice compared with WT controls (P < 0.01), and treatment with losartan reduced it to WT levels (P = 0.80). In contrast, enalapril treatment had significantly less effect on ERK1/2 activation than losartan (P < 0.001); in fact, it was no more effective than placebo (P = 0.50). JNK1 and p38 activation was similar in Fbn1C1039G/+ and WT mice; both losartan and enalapril caused a modest reduction in JNK1 activation (P < 0.01), but neither had any effect on p38 activation (fig. S10). Thus, the biochemical status of the noncanonical ERK1/2, but not the canonical Smad, TGFβ signaling cascade correlated with the therapeutic effects of these agents. In keeping with this finding, losartan had a reduced ability to lower ERK1/2 activation in Fbn1C1039G/+ mice lacking the AT2 receptor (P < 0.01) (Fig. 3C). By contrast, there was no significant difference in Smad2, JNK1, or p38 activation in losartan-treated Fbn1C1039G/+ mice that did or did not express AT2 (fig. S11).

To assess for a contribution of other components of the renin-angiotensin-aldosterone system, we treated Fbn1C1039G/+ mice with the aldosterone receptor antagonist spironolactone (24). We found no significant inhibition of aortic root growth over 7 months time (P = 0.23) (fig. S12).

In conclusion, dual blockade of AT1 receptor–mediated ERK1/2 activation and AT2 receptor–mediated ERK1/2 inhibition, as occurs either with the use of ACEi in Fbn1C1039G/+ mice or the use of losartan in AT2KO:Fbn1C1039G/+ mice, results in no net change in ERK1/2 activation status and adds a very modest therapeutic benefit. By contrast, losartan reduces ERK1/2 phosphorylation through a combination of both inhibiting AT1 receptor–mediated ERK activation and by shunting AngII signaling through the AT2 receptor. This indicates that, in the presence of AT1 receptor blockade, ongoing AT2 receptor signaling is required for the attenuation of ERK phosphorylation and that enalapril's lack of effect on ERK is attributable to the loss of AT2 receptor signaling potential with this agent (Fig. 3D). Given that the small reduction in aortic root growth in Fbn1C1039G/+ mice achieved by enalapril in this study was comparable to that achieved previously by propanolol (1), this suggests that its small beneficial effect may well have been mediated by blood pressure reduction. Although the concordant effects of prior manipulations and therapies on canonical and noncanonical TGFβ signaling made it impossible to dissect their relative contributions, the differential effects of enalapril treatment suggest that TGFβ-mediated ERK1/2 activation is the predominant driver of aneurysm progression in MFS. In light of this, analysis of ERK1/2 activation status may permit the optimization of dosing regimens for losartan or other ARBs in ongoing or future clinical trials in people with MFS. Furthermore, focused attention on the ERK1/2 signaling cascade may unveil new therapeutic targets in the treatment of aortic aneurysm disease.

Supplementary Material

SOM

Acknowledgments

Supported by the NIH (H.C.D., D.P.J.); Howard Hughes Medical Institute (H.C.D.); the National Marfan Foundation (H.C.D., J.P.H., J.J.D.); the Cellular and Molecular Medicine Training Program, Johns Hopkins School of Medicine (J.J.D.); and the Smilow Center for Marfan Syndrome Research (H.C.D.). We thank T. Inagami for the AT2KO mice. Johns Hopkins University and the authors (H.C.D., J.P.H., D.P.J.) have filed a patent relating to the use of TGFβ antagonists, including AT1 receptor blockers, for the treatment of Marfan syndrome.

Footnotes

Supporting Online Material

www.sciencemag.org/cgi/content/full/332/6027/361/DC1

Materials and Methods

Figs. S1 to S12

References

References and Notes

1. Habashi JP, et al. Science. 2006;312:117. [PMC free article] [PubMed]
2. Neptune ER, et al. Nat. Genet. 2003;33:407. [PubMed]
3. Ng CM, et al. J. Clin. Invest. 2004;114:1586. [PMC free article] [PubMed]
4. Cohn RD, et al. Nat. Med. 2007;13:204. [PubMed]
5. Wolf G, Ziyadeh FN, Stahl RA. J. Mol. Med. 1999;77:556. [PubMed]
6. Fukuda N, et al. Am. J. Hypertens. 2000;13:191. [PubMed]
7. Naito T, et al. Am. J. Physiol. Renal Physiol. 2004;286:F278. [PubMed]
8. Jones ES, Black MJ, Widdop RE. J. Mol. Cell. Cardiol. 2004;37:1023. [PubMed]
9. Rodríguez-Vita J, et al. Circulation. 2005;111:2509. [PubMed]
10. Nagashima H, et al. Circulation. 2001;104(suppl. 1):I282. [PubMed]
11. Daugherty A, Manning MW, Cassis LA. Br. J. Pharmacol. 2001;134:865. [PMC free article] [PubMed]
12. Nagashima H, et al. J. Vasc. Surg. 2002;36:818. [PubMed]
13. Ulmasov B, Xu Z, Tetri LH, Inagami T, Neuschwander-Tetri BA. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;296:G284. [PubMed]
14. Akishita M, et al. J. Clin. Invest. 1999;103:63. [PMC free article] [PubMed]
15. Brooke BS, et al. N. Engl. J. Med. 2008;358:2787. [PMC free article] [PubMed]
16. Yetman AT, Bornemeier RA, McCrindle BW. Am. J. Cardiol. 2005;95:1125. [PubMed]
17. Ahimastos AA, et al. JAMA. 2007;298:1539. [PubMed]
18. Materials and methods are available as supporting material on Science Online.
19. Ichiki T, et al. Nature. 1995;377:748. [PubMed]
20. Judge DP, et al. J. Clin. Invest. 2004;114:172. [PMC free article] [PubMed]
21. Siragy HM, Inagami T, Ichiki T, Carey RM. Proc. Natl. Acad. Sci. U.S.A. 1999;96:6506. [PubMed]
22. Patten RD, et al. Clin. Sci. 2003;104:109. [PubMed]
23. Holm T, et al. Science. 2011;332:358. [PubMed]
24. Sakurabayashi-Kitade S, et al. Atherosclerosis. 2009;206:54. [PubMed]